Business
HOPE Therapeutics, an NRx Subsidiary (Nasdaq:NRXP) Announces opening of Palm Beach, FL Clinic offering One Day treatment for Depression and PTSD
Published results have shown 87% clinical response to non-invasive Transcranial Magnetic Stimulation with neuroplastic medications.Clinical leadership by
About this update from Nrx Pharmaceuticals, Inc.
[{"type":"text","content":"Published results have shown 87% clinical response to non-invasive Transcranial Magnetic Stimulation with neuroplastic medications.Clinical leadership by physicians trained at Harvard, Johns Hopkins, Georgetown, and other leading Universities.Now accepting patients, call 1-833-4HOPETMS WEST PALM BEACH, Fla., March 09, 2026 (GLOBE NEWSWIRE) -- HOPE Therapeutics, a subsidiary of NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), today announced the opening of its Palm Beach, FL clinic location dedicated to the treatment of Depression and PTSD with an interventional psychiatry approach that includes ketamine1 and other neuroplastic drugs, transcranial magnetic stimulation (TMS), and hyperbaric oxygen, combined with physician-led psychotherapy. This clinic location is the most recent addition to HOPE’s growing network of clinics. Peer-reviewed scientific publications have shown an 87% clinical response rate with a short-term treatment protocol in patients with treatment-resistant depression. With the addition of hyperbaric oxygen therapy, pilot programs have shown a 90% rate of return to full function in patients with depression and post-traumatic stress disorder. TMS has also been shown in some studies to demonstrate improved memory and cognition in some patients with Alzheimer’s disease and Traumatic Brain Injury. HOPE previously announced a nationwide partnership with neurocare AG and expects to bring the latest developments in the non-invasive treatment of these conditions to this flagship location. “Prior to the advent of modern neuroplastic therapies for depression, PTSD, and related conditions, patients were primarily treated with traditional antidepressants which are now understood to work only 37% of the time and to have a broad array of negative side effects. In severe cases, the only FDA-approved treatment was electroshock therapy. We at HOPE are thrilled to be able to offer state-of-the-art neuroplastic therapy with a potential for rapid return to functional daily life, often without the need for daily medications,” said Dr. Jonathan Javitt, CEO of HOPE Therapeutics. The clinical results that have been published in the medical literature are based on a broad array of patients and may or may not reflect the results achieved by any individual patient. About HOPE Therapeutics, Inc. HOPE Therapeutics, Inc. (www.hopetherapeutics.com),...